Ligritinib
Based on 1 Customer Validation
Ligritinib (AB801) is an orally active AXL receptor tyrosine kinase inhibitor, with a IC50 of 1.8 nM, Ki of 0.024 nM, and Kd of 0.093 nM against human targets. It exhibits broad selectivity against the human kinome, including high selectivity for MERTK and TYRO3. Ligritinib blocks the AXL signaling pathway independent of dimerization inducers, and acts as both a tumor growth inhibitor and an AXL inducer. Ligritinib can be used in research related to clear cell renal cell carcinoma, advanced solid tumors, and non-small cell lung cancer.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 98.08%
- CAS No.: 3024588-48-2
- 화학식: C33H32N6O
- 분자량:528.65
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
Biological Activity
|
Axl 1.8 nM (IC50) |
Axl 0.024 nM (Ki) |
Axl 0.093 nM (Kd) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK-293T | IC50 |
68 nM
|
Inhibition of AXL autophosphorylation in transiently transfected human HEK293T cells incubated for 1 h in 100% human serum, measured via pAXL ELISA with NanoLuc activity readout.
Inhibition of AXL autophosphorylation in transiently transfected human HEK293T cells incubated for 1 h in 100% human serum, measured via pAXL ELISA with NanoLuc activity readout.
|
40407274 |
Ligritinib (1 h) inhibits the autophosphorylation of AXL in transiently transfected HEK293T cells, with an IC50 of 68 nM in 100% human serum[1].
Ligritinib (10 μM) inhibits hERG channels by 46%[1].
Ligritinib exhibits limited direct inhibitory effects on human CYP isoenzymes, with its IC50 values ranging from 5.6 μM (CYP3A4-T) to >100 μM (CYP1A2, CYP2B6)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nu/Nu (female, 6-10 weeks old, human clear-cell renal cell carcinoma 786-O xenograft model via subcutaneous injection of 4 × 106 cells in right flank)[1]
-
Dosage:10 mg/kg; 30 mg/kg
-
Administration:p.o.; daily
-
Result:Did not result in tumor growth inhibition compared to vehicle control when administered as single-agent at 10 mg/kg or 30 mg/kg.
Caused a statistically significant reduction in tumor volume compared to vehicle, single-agent sunitinib, or single-agent Ligritinib when combined with Sunitinib at 30 mg/kg.
Showed statistically significant tumor growth inhibition compared to vehicle control but not compared to single-agent Sunitinib or Ligritinib when combined with sunitinib at 10 mg/kg.
Significantly increased plasma levels of soluble AXL at 30 mg/kg, indicative of AXL inhibition.
Was well-tolerated, with no significant loss of body weight observed.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 3024588-48-2
-
Appearance Solid
-
분자량 528.65
-
화학식 C33H32N6O
-
Color Off-white to pink
-
SMILES
CC(C=CC=N1)=C1C(C=N2)=CC=C2C3=NNC4=NC=C(C=C43)C5=CC6=C(C=C5)CC[C@@H](CC6)N7C8COCC7C8
-
Synonyms
AB801
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
순도&문서
-
Data Sheet (278 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Ligritinib Related Classifications
HY-176205 Related Classifications
Powered by Bioz